News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
287,101 Results
Type
Article (15187)
Company Profile (299)
Press Release (271608)
Multimedia
Podcasts (95)
Webinars (12)
Section
Business (79952)
Career Advice (164)
Deals (13395)
Drug Delivery (43)
Drug Development (50805)
Employer Resources (31)
FDA (5898)
Job Trends (5186)
News (145366)
Policy (10081)
Tag
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (936)
Accelerated approval (26)
Adcomms (14)
Allergies (100)
Alliances (21762)
ALS (159)
Alzheimer's disease (1125)
Antibody-drug conjugate (ADC) (362)
Approvals (6163)
Artificial intelligence (344)
Autoimmune disease (229)
Automation (10)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (117)
Biotechnology (230)
Bladder cancer (119)
Brain cancer (57)
Breast cancer (410)
Cancer (3825)
Cardiovascular disease (282)
Career advice (152)
Career pathing (9)
CAR-T (266)
CDC (7)
Celiac Disease (1)
Cell therapy (705)
Cervical cancer (21)
Clinical research (44647)
Collaboration (1409)
Company closure (3)
Compensation (727)
Complete response letters (54)
COVID-19 (1120)
CRISPR (104)
C-suite (729)
Cystic fibrosis (119)
Data (5466)
Denatured (20)
Depression (112)
Dermatology (53)
Diabetes (300)
Diagnostics (1438)
Digital health (16)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (250)
Drug pricing (52)
Drug shortages (3)
Duchenne muscular dystrophy (267)
Earnings (32726)
Editorial (33)
Employer branding (4)
Employer resources (29)
Events (53056)
Executive appointments (682)
FDA (8015)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (15)
Frontotemporal dementia (30)
Funding (1162)
Gene editing (222)
Generative AI (30)
Gene therapy (596)
GLP-1 (553)
Government (1180)
Grass and pollen (3)
Guidances (172)
Healthcare (6664)
HIV (26)
Huntington's disease (50)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (83)
Immunology and inflammation (231)
Immuno-oncology (73)
Indications (126)
Infectious disease (1266)
Inflammatory bowel disease (182)
Inflation Reduction Act (10)
Influenza (54)
Intellectual property (196)
Interviews (18)
IPO (7365)
IRA (13)
Job creations (869)
Job search strategy (130)
JPM (41)
Kidney cancer (9)
Labor market (28)
Layoffs (251)
Leadership (13)
Legal (1403)
Liver cancer (44)
Longevity (23)
Lung cancer (500)
Lymphoma (288)
Machine learning (33)
Management (7)
Manufacturing (500)
MASH (152)
Medical device (2697)
Medtech (2713)
Mergers & acquisitions (6742)
Metabolic disorders (861)
mRNA (151)
Multiple sclerosis (120)
NASH (14)
Neurodegenerative disease (304)
Neuropsychiatric disorders (81)
Neuroscience (2242)
Neurotech (1)
NextGen: Class of 2026 (2036)
Non-profit (875)
Now hiring (39)
Obesity (386)
Opinion (139)
Ovarian cancer (173)
Pain (131)
Pancreatic cancer (211)
Parkinson's disease (284)
Partnered (12)
Patents (374)
Patient recruitment (478)
Peanut (47)
People (27102)
Pharmaceutical (42)
Pharmacy benefit managers (6)
Phase 1 (15821)
Phase 2 (20785)
Phase 3 (13092)
Pipeline (5556)
Policy (102)
Postmarket research (853)
Preclinical (6728)
Press Release (30)
Prostate cancer (185)
Psychedelics (58)
Radiopharmaceuticals (271)
Rare diseases (841)
Real estate (1456)
Recruiting (12)
Regulatory (10451)
Reports (20)
Research institute (981)
Resumes & cover letters (20)
Rett syndrome (35)
RNA editing (26)
RSV (24)
Schizophrenia (144)
Series A (228)
Series B (159)
Service/supplier (1)
Sickle cell disease (90)
Special edition (19)
Spinal muscular atrophy (125)
Sponsored (17)
Startups (2025)
State (1)
Stomach cancer (5)
Supply chain (38)
Tariffs (19)
The Weekly (73)
Vaccines (385)
Venture capital (84)
Weight loss (208)
Women's health (42)
Worklife (2)
Date
Last 7 days (538)
Last 30 days (1985)
Last 365 days (17776)
2026 (7197)
2025 (18098)
2024 (20537)
2023 (22411)
2022 (26822)
2021 (27808)
2020 (23354)
2019 (16222)
2018 (11736)
2017 (13745)
2016 (11839)
2015 (14353)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (72)
Alaska (2)
Arizona (82)
Arkansas (6)
Asia (18583)
Australia (3185)
California (8319)
Canada (2135)
China (956)
Colorado (301)
Connecticut (312)
Delaware (283)
Europe (39959)
Florida (1064)
Georgia (245)
Hawaii (2)
Idaho (17)
Illinois (483)
India (44)
Indiana (193)
Iowa (8)
Japan (286)
Kansas (83)
Kentucky (11)
Louisiana (12)
Maine (12)
Maryland (862)
Massachusetts (6585)
Michigan (124)
Minnesota (293)
Mississippi (3)
Missouri (35)
Montana (17)
Nebraska (6)
Nevada (45)
New Hampshire (22)
New Jersey (1901)
New Mexico (13)
New York (2068)
North Carolina (970)
North Dakota (7)
Northern California (4194)
Ohio (210)
Oklahoma (11)
Oregon (23)
Pennsylvania (1535)
Puerto Rico (11)
Rhode Island (27)
South America (216)
South Carolina (12)
Southern California (3331)
Tennessee (49)
Texas (1122)
United States (27470)
Utah (114)
Virginia (171)
Washington D.C. (37)
Washington State (683)
West Virginia (1)
Wisconsin (54)
287,101 Results for "eikon therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
May 11, 2026
·
8 min read
IPO
Eikon, Veradermics, Announce IPO Targets as Cautious Optimism Propels Biotech Market
Cancer-focused Eikon Therapeutics is seeking $273.5 million in its bid to trade on the Nasdaq, while hair growth specialist Veradermics is looking for $181.1 million in its foray onto the New York Stock Exchange.
January 29, 2026
·
3 min read
·
Tristan Manalac
Press Releases
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
March 30, 2026
·
9 min read
Press Releases
Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering
February 5, 2026
·
3 min read
Press Releases
Eikon Therapeutics Announces the Election of David W. Meline to its Board of Directors
December 3, 2025
·
2 min read
Funding
Eikon Adds Nearly $351M to Conquer Phase III Development in Melanoma
Eikon’s lead candidate, EIK1001, is being tested for advanced melanoma. The candidate is currently in late-stage development, which the biotech will fund using Wednesday’s series D raise.
February 26, 2025
·
1 min read
·
Tristan Manalac
IPO
2026 IPO Train Keeps Chugging as AgomAb, SpyGlass Eye Nasdaq Debut
Two more biopharma companies—the hair-growth specialist Veradermics and cancer-focused Eikon Therapeutics—have announced their IPOs this year. Meanwhile, Aktis Oncology began trading publicly earlier this month.
January 19, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Eikon Therapeutics to Present New Phase 2 Data on EIK1001 in First-Line Non-Small Cell Lung Cancer at ESMO 2025
October 16, 2025
·
4 min read
Press Releases
Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual Meeting
May 29, 2025
·
5 min read
Biotech Bay
Eikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Eikon Therapeutics Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
May 28, 2024
·
3 min read
1 of 28,711
Next
